Artgen Biotech
ABIO · MOEX
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | VEGF165 gene therapy (angiogenic plasmid)Gene therapy / editing | Atherosclerotic Cardiovascular Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.